Zum Hauptinhalt springen
xMedica

NCT07830719ClinicalTrials.gov

Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study of YMI024 to Assess Efficacy in Reducing Inflammatory Markers, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and…

Phase 2180 Teilnehmende gesucht23 Studienzentren5 Länder

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 3 days after the recorded start)First posted 2026-09-21; recorded start 2026-09-18
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleSMALL

A small study, international in scope: 180 participants (target), run at 23 sites, across 5 countries.

How this score is built
  • Enrolment21/40

    180 participants (target)

  • Site count0/25

    1 sites

  • Country count0/15

    Single country

  • Planned duration5/10

    Planned over about 13 months

  • Sponsor scale10/10

    Novartis Pharmaceuticals has led 1,133 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and residual inflammatory risk defined by elevated high-sensitivity C-reactive protein (hsCRP) (≥2 mg/L)

Participants are randomized in a 1:1:1:1:1:1 ratio to one of the six arms, with stratification by comorbidity status at randomization: CAD-only, CAD+ (Heart Failure) HF, and CAD+Chronic Kidney Disease (CKD), and receive study medication on top of stable standard-of-care therapies. The study employs double-blinding, concealing treatment allocation from participants, Investigators, Sponsor, and study staff, with identical packaging and labelling, schedule of administration and appearance for all study drugs.

Erkrankungen

  • Coronary Artery Disease

Eignung

Eignung
GeschlechtAlle
Alter18 Years – 80 Years
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: 1. Signed informed consent must be obtained prior to any study specific procedures, and participant able to understand and comply with study requirements. 2. Male and female participants aged between 18-80 years (inclusive) at Screening. 3. Documented stable CAD as evidenced by presence of at least one of the following criteria: 1. Documented history of spontaneous (Type 1) myocardial infarction (MI) of presumed atherosclerotic origin that occurred at least 30 days before the start of Screening. If a Pre-screening visit is conducted, the MI must have occurred at least 30 days before that visit. Diagnosis of the qualifying MI should be based on medical records and Investigator's judgment. 2. Prior coronary revascularization (i.e. percutaneous coronary intervention (PCI) at least 30 days prior, or coronary artery bypass grafting (CABG), at least 6 months prior to Screening). * Any prior PCI must have occurred at least 30 days prior to the Screening Visit (or if conducted, prior to the Pre screening visit). * Any prior CABG must have occurred at least 6 months (i.e. 26 weeks) prior to the Screening (or if conducted, prior to the Pre-screening) Visit. 3. Angiographic or CT-imaging (e.g., Multi Detector Computed Tomography/ Computed Tomography Angiography (MDCT/CTA)) evidence of coronary atherosclerosis: ≥50% stenosis in at least one major epicardial coronary artery. 4. Coronary artery calcium (CAC) score of ≥300 AU by computed tomography. To ensure adequate representation of patients with clinically relevant comorbidities and to enable prespecified subgroup analyses, the trial will include participants with key comorbidities as follows: i. Moderate CKD Participants with moderate (Stage 3a/3b) kidney disease (CKD) defined as: Estimated Glomerular Filtration Rate (eGFR) ≥30 and ≤60 mL/min/1.73 m² (CKD EPI formula) at Screening. ii. Chronic HF Participants with a history of chronic heart failure (HF) defined as: * NYHA Class II-III symptoms of HF requiring ongoing treatment with diuretics (loop diuretics, thiazide diuretics, and/or mineralocorticoid receptor antagonists) for ≥30 days prior to Screening, AND * LVEF ≤40%, assessed by any standard modality (e.g., echocardiography, cardiac Magnetic Resonance Imaging (MRI), CT, MUGA, or ventricular angiography) on the most recent assessment within 12 months prior to Screening. 4. Participants must have hsCRP levels ≥2 mg/L at two timepoints during Screening. Screening values must be separated by a minimum of 7 days. The initial hsCRP value must be a minimum of 30 days after a qualifying MI or after any PCI performed separately from the qualifying MI, or 6 months after CABG. Note: Participants who choose to enter the optional Pre-screening period must have an hsCRP level, measured at a local laboratory, that is considered by the Investigator to be ≥2 mg/L. This Pre-screening hsCRP value (measured at the local laboratory) must be obtained at least 30 days after a qualifying MI or after any PCI performed separately from the qualifying MI, or 6 months after a CABG. Irrespective of any Pre-screening hsCRP value, all participants must have two central laboratory hsCRP levels ≥2 mg/L at the two Screening visits to be eligible for randomization into the study. Exclusion Criteria: 1. Participants with recent major cardiovascular events or procedures, including: * myocardial infarction, unstable angina, or percutaneous coronary intervention within 30 days prior to Screening (or Pre-screening, if conducted), or * coronary artery bypass grafting or other cardiac surgery within 6 months prior to Screening (or Pre-screening, if conducted). 2. Any major (cardiac or non-cardiac) surgical, interventional or endoscopic procedure (e.g: Percutaneous carotid intervention, carotid or peripheral arterial revascularization), or stroke, Transient ischemic attack (TIA), or acute limb ischemia within 12 weeks prior to Screening or Pre-screening, where applicable). 3. Participants with a known systemic autoimmune or inflammatory disease (e.g., Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA)); clinically active diverticulitis or inflammatory bowel disease within 12 months prior to Screening; or a history of gastrointestinal perforation. 4. Patients with suspected or proven immunocompromised state at Screening (e.g., clinical diagnosis of Human Immunodeficiency Virus (HIV) or on antiretroviral therapy, absolute neutrophil count ≤1000/mm3) or any other medical condition in the opinion of the Investigator places the patient at unacceptable risk by receiving immunomodulatory therapy. 5. Known or suspected active infection, or chronic or recurrent infectious disease, including but not limited to: * Hepatitis B / Hepatitis C: Positive HBsAg, positive anti-HBc, positive anti-HBs, or positive anti-Hepatitis C Virus (HCV) at Screening. * Note: Participants positive for anti-HBs after HBV vaccination but negative for HBsAg and anti-HBc are eligible per local guidelines and Sponsor agreement. * Note: Participants positive for anti-HBc but negative for HBV Deoxyribonucleic Acid (DNA) receiving prophylactic HBV antiviral treatment (e.g., entecavir, lamivudine) are eligible per local guidelines and Sponsor agreement. * Note: Participants positive for anti-HCV but consistently negative for HCV RNA \>6 months after HCV antiviral treatment are eligible per local guidelines and Sponsor agreement. * Tuberculosis (TB): Active or latent TB as indicated by a positive QuantiFERON® TB Gold Plus test or T-SPOT® TB test at Screening. * Any other known active or suspected active infection, or chronic infection, or history of ongoing, chronic, or major recurrent infectious disease. 6. Participants with any of the following renal or hepatic abnormalities at Screening are excluded: 1. Renal dysfunction with Estimated Glomerular Filtration Rate (eGFR) \<30 mL/min/1.73 m² (using CKD-EPI formula; s://.kidney.org/professionals/gfr\_calculator). 2. Evidence of hepatic disease as determined by any one of the following: Aspartate Aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) or Alanine Aminotransferase (ALT) (Serum Glutamic Pyruvic Transaminase (SGPT)) \>3× ULN, or bilirubin \>1.5 mg/dL at Screening (for patients with Gilbert's syndrome, total bilirubin \<2× ULN is allowed). 7. Current or prior history of severe heart failure of New York Heart Association (NYHA) Class IV. Other protocol-defined inclusion/exclusion criteria may apply

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhasePhase 2
ZuteilungRandomisiert
InterventionsmodellPARALLEL
Primäres ZielTREATMENT
VerblindungQUADRUPLE (4)
Teilnahme180 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Novartis Pharmaceuticals Sponsor

Studienarme und Interventionen

  • YMI024 Dose 1EXPERIMENTAL

    Participants receive YMI024 Dose 1 in addition to standard-of-care therapies.

  • YMI024 Dose 2EXPERIMENTAL

    Participants receive YMI024 Dose 2 in addition to standard-of-care therapies.

  • YMI024 Dose 3EXPERIMENTAL

    Participants receive YMI024 Dose 3 in addition to standard-of-care therapies.

  • YMI024 Dose 4EXPERIMENTAL

    Participants receive YMI024 Dose 4 in addition to standard-of-care therapies.

  • YMI024 Dose 5EXPERIMENTAL

    Participants receive YMI024 Dose 5 in addition to standard-of-care therapies.

  • PlaceboPLACEBO_COMPARATOR

    Participants receive a matching placebo in addition to standard-of-care therapies

Interventionen

  • Arzneimittel Placebo

    matching placebo

  • Arzneimittel YMI024

    YMI024 in different doses

Endpunkte

  1. Primärer Endpunkt

    Change from baseline in log-transformed IL-6

    Change from baseline in log-transformed Interleukin-6 (IL-6) to evaluate the dose-response relationship using the Multiple Comparison Procedures (MCP) component of the Multiple Comparison Procedure-Modelling (MCP-Mod) methodology

    Zeitrahmen Baseline and approximately 3 months

  2. Sekundärer Endpunkt

    Change from baseline in log-transformed IL-6

    Change from baseline in log-transformed IL-6 to characterize the dose-response relationship for YMI024 in IL-6 using the model-based (Mod) component of the MCP-Mod methodology

    Zeitrahmen Baseline and approximately 3 months

  3. Sekundärer Endpunkt

    Change from baseline in log-transformed hsCRP

    Change from baseline in log-transformed high-sensitivity C-reactive protein (hsCRP)

    Zeitrahmen Baseline and approximately 3 months

  4. Sekundärer Endpunkt

    Responder status - hsCRP <2 mg/L

    Responder status (Yes/No), defined as hsCRP \<2 mg/L

    Zeitrahmen Approximately 3 months

  5. Sekundärer Endpunkt

    Responder status - hsCRP <1 mg/L

    Responder status (Yes/No), defined as hsCRP \<1 mg/L

    Zeitrahmen Approximately 3 months

  6. Sekundärer Endpunkt

    Number of participants with adverse events

    Number of participants with adverse events, including abnormal vital signs, ECGs, and laboratory assessments

    Zeitrahmen Approximately 4 months

Daten

Daten
Startdatum18. September 2026 (tatsächlich)
Primärer Abschluss15. August 2027 (geschätzt)
Abschluss15. August 2027 (geschätzt)
Erstveröffentlichung21. September 2026 (tatsächlich)
Zuletzt aktualisiert15. Oktober 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtOktober 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

23 Studienzentren rekrutieren

Australia

Australia
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteAdelaideSouth AustraliaRekrutiert
Novartis Investigative SiteFrankstonVictoriaRekrutiert
Novartis Investigative SiteMelbourneVictoriaRekrutiert
Novartis Investigative SiteMulgraveVictoriaRekrutiert

Germany

Germany
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteBerlinRekrutiert
Novartis Investigative SiteKaiserslauternRhineland-PalatinateRekrutiert
Novartis Investigative SiteMannheimRekrutiert
Novartis Investigative SitePirnaRekrutiert
Novartis Investigative SiteStuttgartBaden-WurttembergRekrutiert

Japan

Japan
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteKamakuraKanagawaRekrutiert
Novartis Investigative SiteKasugaiAichi-kenRekrutiert
Novartis Investigative SiteMatsubaraOsakaRekrutiert
Novartis Investigative SiteMatsudoChibaRekrutiert

United Kingdom

United Kingdom
EinrichtungStadtBundesland oder RegionStatus
Novartis Investigative SiteLondonRekrutiert

United States

United States
EinrichtungStadtBundesland oder RegionStatus
Pharma Tex ResearchAmarilloTexasRekrutiert
AMR MiamiCoral GablesFloridaRekrutiert
Eastern Shore Research InstituteFairhopeAlabamaRekrutiert
G and L Research LLCFoleyAlabamaRekrutiert
Anderson Medical ResearchFt. WashingtonMarylandRekrutiert
Biopharma Informatic LLCLos AngelesCaliforniaRekrutiert
MD Medical ResearchOxon HillMarylandRekrutiert
Alliance for Multispecialty ResearchWichitaKansasRekrutiert
Selma Medical AssociatesWinchesterVirginiaRekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 15. Oktober 2026

    Abschlussdatum nach vorne verschoben

    Primary completion advanced 65 days

    2027-10-192027-08-15

  2. 15. Oktober 2026

    Studienzentrum hinzugefügt

    22 sites added (23 total)

    123

  3. 24. September 2026

    Status geändert

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  4. 24. September 2026

    Rekrutierung eröffnet

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  5. 24. September 2026

    Abschlussdatum nach hinten verschoben

    Primary completion delayed 33 days

    2027-09-162027-10-19

  6. 24. September 2026

    Studienzentrum hinzugefügt

    1 site added (1 total)

    01